High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1899-1906

  Zaucha, Renata ^a   Gooley, Ted ^b,d   Holmberg, Leona ^b,c,d   Gopal, Ajay K ^b,c,d   Press, Oliver ^b,c,d   Maloney, David ^b,c,d   Bensinger, William I ^b,c,d  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Fred Hutchinson Cancer Research Center   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous SCT; High dose chemotherapy

Indexed keywords

ACICLOVIR; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ASPERGILLOSIS; BACTERIAL INFECTION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; COMORBIDITY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GRAFT INFECTION; HEART ARREST; HEART DISEASE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LUNG DISEASE; LUNG INSUFFICIENCY; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; SCORING SYSTEM; SKIN DISEASE; STEM CELL MOBILIZATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VEIN OCCLUSION; VIRUS INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CARMUSTINE; CYTARABINE; DRUG EVALUATION; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 55049132537     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802340184     Document Type: Conference Paper

References (41)

1. Coiffier, B. (2005) State-of-the-art therapeutics: Diffuse large B-cell lymphoma. J Clin Oncol, 23, pp. 6387-6393.
2. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. Bouabdallah, R. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
4. Fisher, S. G. and Fisher, R. I. (2004) The epidemiology of non-Hodgkin's lymphoma. Oncogene, 23, pp. 6524-6534.
5. Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K. Hoskins, P. et al. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, pp. 1857-1861.
6. Milpied, N., Deconinck, E., Gaillard, F., Delwail, V., Foussard, C. Berthou, C. et al. (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med, 350, pp. 1287-1295.
7. Kaiser, U., Uebelacker, I., Abel, U., Birkmann, J., Trumper, L. Schmalenberg, H. et al. (2002) Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol, 20, pp. 4413-4419.
8. Nademanee, A., Molina, A., Dagis, A., Snyder, D., O'Donnell, M. Parker, P. et al. (2000) Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma, 1, pp. 46-54.
9. Schmitz, N., Kloess, M., Reiser, M., Berdel, W., Metzner, B. Dorken, B. et al. (2006) Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer, 106, pp. 136-145.
10. Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B. Brice, P. et al. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol, 18, pp. 3025-3030.
11. Mounier, N., Gisselbrecht, C., Briere, J., Haioun, C., Feugier, P. Offner, F. et al. (2004) Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 22, pp. 2826-2834.
12. Gianni, A. M., Bregni, M., Siena, S., Brambilla, C., Di Nicola, M Lombardi, F. et al. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med, 336, pp. 1290-1297.
13. Bertz, H., Zeiser, R., Lange, W., Fetscher, S., Waller, C. and Finke, J. (2004) Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol, 15, pp. 1419-1424.
14. Intragumtornchai, T., Prayoonwiwat, W., Numbenjapon, T., Assawametha, N., O'Charoen, R. and Swasdikul, D. (2000) CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma, 1, pp. 219-225.
15. Freedman, A. S., Neuberg, D., Mauch, P., Soiffer, R., Anderson, K. and Fisher, D. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, pp. 3325-3333.
16. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. Bron, D. et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
17. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. Haenel, M. et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet, 359, pp. 2065-2071.
18. Schiffman, K., Buckner, C. D., Maziarz, R., Maloney, D., Appelbaum, F. Press, O. et al. (1997) High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant, 3, pp. 261-226.
19. Weaver, C. H., Schwartzberg, L., Zhen, B., Mangum, M., Leff, R. Tauer, K. et al. (1997) High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers. Bone Marrow Transplant, 20, pp. 753-760.
20. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R. Bosly, A. et al. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, pp. 4284-4289.
21. Gopal, A. K., Gooley, T. A., Golden, J. B., Maloney, D., Bensinger, W. Petersdorf, S. et al. (2001) Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant, 27, pp. 593-599.
22. Weaver, C. H., Bensinger, W. I., Appelbaum, F. R., Lilleby, K., Sandmaier, B. Brunvand, M. et al. (1994) Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant, 14, pp. 813-819.
23. Colombat, P., Biron, P., Laporte, J. P., Cahn, J. Y., Herve, P. Gorin, N. C. et al. (1990) BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer, 26, p. 858.
24. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D. C. and Goldstone, A. H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol, 13, pp. 588-595.
25. Bensinger, W., Appelbaum, F., Rowley, S., Storb, R., Sanders, J. Lilleby, K. et al. (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol, 13, pp. 2547-2555.
26. Demirer, T., Buckner, C. D. and Bensinger, W. I. (1996) Optimization of peripheral blood stem cell mobilization. Stem Cells, 14, pp. 106-116.
27. Bearman, S. I., Appelbaum, F. R., Buckner, C. D., Petersen, F. B., Fisher, L. D. Clift, R. A. et al. (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol, 6, pp. 1562-1568.
28. Jantunen, E., Kuittinen, T. and Nousiainen, T. (2003) BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma, 44, pp. 1151-1158.
29. Wang, E. H., Chen, Y. A., Corringham, S., Bashey, A., Holman, P. Ball, E. D. et al. (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant, 34, pp. 581-587.
30. Jo, J. C., Kang, B. W., Jang, G., Sym, S. J., Lee, S. S. Koo, J. E. et al. (2007) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol, 21, p. 21.
31. Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Kwak, L. W. Long, G. D. et al. (1991) The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol, 2, pp. 47-50.
32. Caballero, M. D., Perez-Simon, J. A., Iriondo, A., Lahuerta, J. J., Sierra, J. Marin, J. et al. (2003) High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 14, pp. 140-151.
33. Gopal, A. K., Gooley, T. A., Maloney, D. G., Petersdorf, S. H., Eary, J. F. Rajendran, J. G. et al. (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood, 102, pp. 2351-2357.
34. Gutierrez-Delgado, F., Maloney, D. G., Press, O. W., Golden, J., Holmberg, L. A. Maziarz, R. T. et al. (2001) Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant, 28, pp. 455-461.
35. Gutierrez-Delgado, F., Holmberg, L., Hooper, H., Petersdorf, S., Press, O. Maziarz, R. et al. (2003) Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant, 32, pp. 279-285.
36. Demirer, T., Ayli, M., Fen, T., Ozcan, M., Arat, M. Buyukberber, S. et al. (2004) High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation. Bone Marrow Transplant, 34, pp. 781-786.
37. Stockerl-Goldstein, K. E., Horning, S. J., Negrin, R. S., Chao, N. J., Hu, W. W. Long, G. D. et al. (1996) Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant, 2, pp. 76-85.
38. Gulati, S., Yahalom, J., Acaba, L., Reich, L., Motzer, R. Crown, J. et al. (1992) Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol, 10, pp. 936-941.
39. Emmanouilides, C., Asuncion, D. J., Wolf, C., Scott, S. and Territo, M. (2003) Localized radiation increases morbidity and mortality after TBI-containing autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant, 32, pp. 863-867.
40. Friedberg, J. W., Neuberg, D., Monson, E., Jallow, H., Nadler, L. M. and Freedman, A. S. (2001) The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant, 7, pp. 446-453.
41. Dawson, L. A., Saito, N. G., Ratanatharathorn, V., Uberti, J. P., Adams, P. T. Ayash, L. J. et al. (2004) Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Int J Radiat Oncol Biol Phys, 59, pp. 208-218.